Company Overview - BeOne Medicines Ltd. is a global oncology company based in Switzerland, focused on discovering and developing innovative cancer treatments that are more accessible to patients worldwide [2] - The company has a diverse pipeline of novel therapeutics targeting both hematology and solid tumors, supported by internal capabilities and collaborations [2] - BeOne has a workforce of over 11,000 employees across six continents, emphasizing its commitment to improving access to medicines for cancer patients [2] Upcoming Events - BeOne Medicines will participate in two investor conferences: the Guggenheim Second Annual Healthcare Innovation Conference on November 10, 2025, and the Jefferies Global Healthcare Conference in London on November 17, 2025 [5] - Live webcasts of these events will be available on the company's investor relations website, with archived replays accessible afterward [1][5] Financial Information - BeOne Medicines is scheduled to announce its third quarter 2025 financial results on November 6, 2025, before the financial markets open [8] - Following the financial results release, the company will host a live webcast with management at 8:00 a.m. ET [8] Recent Developments - BeOne presented new data on its PD-1 inhibitor, TEVIMBRA, at the European Society of Medical Oncology 2025 Congress, showcasing benefits from two pivotal Phase 3 trials [9][10] - The U.S. FDA granted Breakthrough Therapy Designation for sonrotoclax, a next-generation BCL2 inhibitor, for treating adult patients with relapsed or refractory mantle cell lymphoma [11]

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October 17-21. The results reinforce TEVIMBRA's consistent and durable efficacy across lung ca ...